Porton Pharma Solutions Ltd. Reports 2026 First‑Half Financial Results
Porton Pharma Solutions Ltd. (ticker: 300363.SZ), a Chinese company listed on the Shenzhen Stock Exchange, announced its consolidated financial statements for the first half of 2026. The company’s revenue rose 10.42 % year‑over‑year to 1.790 billion CNY, while its net loss widened to 224 million CNY.
Revenue Breakdown
| Segment | Revenue (CNY) | YoY % | Share of Total |
|---|---|---|---|
| Small‑molecule API business | 1.644 billion | +10 % | 92 % |
| Cell and gene therapy business | 55 million | +67 % | 3 % |
| New‑molecule business | 28 million | +27 % | 2 % |
The core small‑molecule API segment remains the company’s principal income source, accounting for the vast majority of sales. Growth in the cell‑and‑gene therapy and new‑molecule businesses is noted, albeit from smaller bases.
Net Loss
The net loss of 224 million CNY reflects higher operating expenses and investment costs during the period. No material changes to the company’s capital structure or balance‑sheet items were reported.
Market Context
- The Shenzhen market opened the day after the release with the ChiNext index up 1.43 %.
- Medical‑biological stocks, including Porton, experienced widespread gains; several companies in the sector hit 20‑point limit‑up, indicating strong investor enthusiasm.
- The overall trading volume on the ChiNext fell compared with the previous day, yet the number of rising stocks surpassed 4,000, showing a broadly positive sentiment.
Company Profile
Porton Pharma Solutions Ltd., headquartered in Chongqing, specializes in the production of drug intermediates and active pharmaceutical ingredients. Founded in 2005 and renamed in 2018, the company manufactures chirally pure intermediates, unnatural amino acids, heterocyclic compounds, and related derivatives. Its market capitalization is approximately 11.9 billion CNY, and the price‑earnings ratio stands at 95.27. The share price closed at 21.89 CNY on 20 August 2026.
The information above is sourced from the company’s 2026 first‑half report and contemporaneous market commentary. No speculative or forward‑looking statements are included.
